CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 28, 2005--POZEN, Inc. (NASDAQ: POZN), a pharmaceutical company focused primarily on products for the treatment of acute and chronic pain, migraine and other pain-related conditions, announced today the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a Marketing Authorization for MT 100 for the acute treatment of migraine.
